BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. The company is headquartered in Stockholm, Stockholm and currently employs 107 full-time employees. The company went IPO on 2017-10-12. The firm focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The firm owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The firm's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The firm also operates through SpineMedical AB.
Follow-Up Questions
What is the price performance of BRCTF stock?
The current price of BRCTF is $32.16, it has decreased 0% in the last trading day.
What are the primary business themes or industries for BioArctic AB?
BioArctic AB belongs to Biotechnology industry and the sector is Health Care
What is BioArctic AB market cap?
BioArctic AB's current market cap is $2.3B
Is BioArctic AB a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for BioArctic AB, including 3 strong buy, 5 buy, 2 hold, 0 sell, and 3 strong sell
